Article

Heidelberg Engineering expands Spectralis product line

Heidelberg Engineering GmbH expands its line of Spectralis retinal imaging products by adding a more economical two-mode, spectral domain-optical coherence tomography (SD-OCT) technology. The expanded family now consists of Spectralis OCT (two modes); Spectralis HRA (five modes); and Spectralis HRA+OCT (six modes).

Heidelberg Engineering GmbH expands its line of Spectralis retinal imaging products by adding a more economical two-mode, spectral domain-optical coherence tomography (SD-OCT) technology. The expanded family now consists of Spectralis OCT (two modes); Spectralis HRA (five modes); and Spectralis HRA+OCT (six modes).

Spectralis OCT offers two imaging modes (SD-OCT and infrared), while the Spectralis HRA+OCT includes four additional imaging modes (autofluorescence, red-free imaging, fluorescein angiography, and ICG angiography). The new model shares three key features with the earlier version: 40,000 A-scans per second, TruTrack eye-tracking technology, and Heidelberg noise reduction (HNR) for image clarity.

The Spectralis instrument captures the OCT cross-sectional scan under constant guidance of one of five fundus imaging modalities. This helps ensure image registration and enables the instruments to track change precisely over time, an advantage over the technical limitations of time-domain OCT, according to the company. In addition, HNR technology significantly improves image quality by eliminating unwanted optical noise in both fundus and OCT images.

Shipment of the product is expected to begin this summer, according to the company.

For more information, visit Heidelberg Engineering at Booth 1541.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.